Which has stronger earnings and valuation, ACAD or VOR?

ACADIA Pharmaceuticals has higher revenue and earnings than Vor Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ACADIA Pharmaceuticals $1.07B 4.54 $391M $2.22 12.72 Vor Biopharma N/A N/A N/A N/A N/A

Does the media refer more to ACAD or VOR?

In the previous week, Vor Biopharma had 6 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 25 mentions for Vor Biopharma and 19 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.73 beat Vor Biopharma's score of 0.22 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 7 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vor Biopharma 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better earnings & valuation, VOR or DYN?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Dyne Therapeutics N/A N/A -$446.21M -$3.33 N/A

Is VOR or DYN more profitable?

Vor Biopharma's return on equity of 0.00% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vor Biopharma N/A N/A N/A Dyne Therapeutics N/A -64.30% -50.33%

Does the media refer more to VOR or DYN?

In the previous week, Vor Biopharma had 22 more articles in the media than Dyne Therapeutics. MarketBeat recorded 25 mentions for Vor Biopharma and 3 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 1.25 beat Vor Biopharma's score of 0.22 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Dyne Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, VOR or CELC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Celcuity N/A N/A -$177.04M -$4.30 N/A

Is VOR or CELC more profitable?

Vor Biopharma's return on equity of 0.00% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Vor Biopharma N/A N/A N/A Celcuity N/A -250.68% -50.23%

Does the media favor VOR or CELC?

In the previous week, Vor Biopharma had 5 more articles in the media than Celcuity. MarketBeat recorded 25 mentions for Vor Biopharma and 20 mentions for Celcuity. Celcuity's average media sentiment score of 0.84 beat Vor Biopharma's score of 0.22 indicating that Celcuity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Celcuity 7 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable earnings & valuation, VOR or PBLS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Parabilis Medicines N/A N/A N/A N/A N/A

Is VOR or PBLS more profitable?

Company Net Margins Return on Equity Return on Assets Vor Biopharma N/A N/A N/A Parabilis Medicines N/A N/A N/A

Does the media refer more to VOR or PBLS?

In the previous week, Vor Biopharma had 18 more articles in the media than Parabilis Medicines. MarketBeat recorded 25 mentions for Vor Biopharma and 7 mentions for Parabilis Medicines. Vor Biopharma's average media sentiment score of 0.22 beat Parabilis Medicines' score of -0.15 indicating that Vor Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Parabilis Medicines 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, VOR or VKTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Viking Therapeutics N/A N/A -$359.64M -$4.66 N/A

Is VOR or VKTX more profitable?

Vor Biopharma's return on equity of 0.00% beat Viking Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vor Biopharma N/A N/A N/A Viking Therapeutics N/A -94.56% -82.75%

Does the media favor VOR or VKTX?

In the previous week, Vor Biopharma had 16 more articles in the media than Viking Therapeutics. MarketBeat recorded 25 mentions for Vor Biopharma and 9 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.55 beat Vor Biopharma's score of 0.22 indicating that Viking Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Viking Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Vor Biopharma (VOR) Competitors

$23.03 -0.26 (-1.12%)

Closing price 04:00 PM Eastern

Extended Trading

$23.02 -0.02 (-0.07%)

As of 07:54 PM Eastern

Compare

VOR vs. ACAD, DYN, CELC, PBLS, and VKTX

Should you buy Vor Biopharma stock or one of its competitors? Vor Biopharma's main competitors and comparable companies include ACADIA Pharmaceuticals (ACAD), Dyne Therapeutics (DYN), Celcuity (CELC), Parabilis Medicines (PBLS), and Viking Therapeutics (VKTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Vor Biopharma compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Vor Biopharma (NASDAQ:VOR) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Vor Biopharma's net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Vor Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
Vor Biopharma	N/A	N/A	N/A

ACADIA Pharmaceuticals has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.73, meaning that its stock price is 73% more volatile than the broader market.

In the previous week, Vor Biopharma had 6 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 25 mentions for Vor Biopharma and 19 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.73 beat Vor Biopharma's score of 0.22 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	7 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vor Biopharma	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

ACADIA Pharmaceuticals has higher revenue and earnings than Vor Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.54	$391M	$2.22	12.72
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

ACADIA Pharmaceuticals presently has a consensus target price of $33.69, suggesting a potential upside of 19.31%. Vor Biopharma has a consensus target price of $43.38, suggesting a potential upside of 88.34%. Given Vor Biopharma's higher possible upside, analysts clearly believe Vor Biopharma is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.82
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are held by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 0.3% of Vor Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

ACADIA Pharmaceuticals beats Vor Biopharma on 8 of the 13 factors compared between the two stocks.

How does Vor Biopharma compare to Dyne Therapeutics?

Vor Biopharma (NASDAQ:VOR) and Dyne Therapeutics (NASDAQ:DYN) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Vor Biopharma's return on equity of 0.00% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Dyne Therapeutics	N/A	-64.30%	-50.33%

In the previous week, Vor Biopharma had 22 more articles in the media than Dyne Therapeutics. MarketBeat recorded 25 mentions for Vor Biopharma and 3 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 1.25 beat Vor Biopharma's score of 0.22 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Dyne Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vor Biopharma presently has a consensus target price of $43.38, suggesting a potential upside of 88.34%. Dyne Therapeutics has a consensus target price of $34.42, suggesting a potential upside of 33.92%. Given Vor Biopharma's higher probable upside, research analysts clearly believe Vor Biopharma is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A

Vor Biopharma has a beta of 1.73, indicating that its share price is 73% more volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 0.3% of Vor Biopharma shares are held by insiders. Comparatively, 9.5% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Vor Biopharma beats Dyne Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Vor Biopharma compare to Celcuity?

Vor Biopharma (NASDAQ:VOR) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A

Vor Biopharma's return on equity of 0.00% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Celcuity	N/A	-250.68%	-50.23%

In the previous week, Vor Biopharma had 5 more articles in the media than Celcuity. MarketBeat recorded 25 mentions for Vor Biopharma and 20 mentions for Celcuity. Celcuity's average media sentiment score of 0.84 beat Vor Biopharma's score of 0.22 indicating that Celcuity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Celcuity	7 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Vor Biopharma currently has a consensus price target of $43.38, suggesting a potential upside of 88.34%. Celcuity has a consensus price target of $153.64, suggesting a potential upside of 67.00%. Given Vor Biopharma's higher probable upside, research analysts plainly believe Vor Biopharma is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

97.3% of Vor Biopharma shares are owned by institutional investors. Comparatively, 63.3% of Celcuity shares are owned by institutional investors. 0.3% of Vor Biopharma shares are owned by company insiders. Comparatively, 13.3% of Celcuity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Vor Biopharma has a beta of 1.73, meaning that its stock price is 73% more volatile than the broader market. Comparatively, Celcuity has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market.

Summary

Vor Biopharma beats Celcuity on 7 of the 10 factors compared between the two stocks.

How does Vor Biopharma compare to Parabilis Medicines?

Vor Biopharma (NASDAQ:VOR) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

In the previous week, Vor Biopharma had 18 more articles in the media than Parabilis Medicines. MarketBeat recorded 25 mentions for Vor Biopharma and 7 mentions for Parabilis Medicines. Vor Biopharma's average media sentiment score of 0.22 beat Parabilis Medicines' score of -0.15 indicating that Vor Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Parabilis Medicines	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Parabilis Medicines	N/A	N/A	N/A

97.3% of Vor Biopharma shares are owned by institutional investors. 0.3% of Vor Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Vor Biopharma presently has a consensus target price of $43.38, suggesting a potential upside of 88.34%. Parabilis Medicines has a consensus target price of $41.67, suggesting a potential upside of 12.40%. Given Vor Biopharma's higher probable upside, equities analysts plainly believe Vor Biopharma is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Parabilis Medicines	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A

Summary

Vor Biopharma beats Parabilis Medicines on 7 of the 8 factors compared between the two stocks.

How does Vor Biopharma compare to Viking Therapeutics?

Vor Biopharma (NASDAQ:VOR) and Viking Therapeutics (NASDAQ:VKTX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

In the previous week, Vor Biopharma had 16 more articles in the media than Viking Therapeutics. MarketBeat recorded 25 mentions for Vor Biopharma and 9 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.55 beat Vor Biopharma's score of 0.22 indicating that Viking Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Viking Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Vor Biopharma's return on equity of 0.00% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Viking Therapeutics	N/A	-94.56%	-82.75%

97.3% of Vor Biopharma shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 0.3% of Vor Biopharma shares are owned by insiders. Comparatively, 5.3% of Viking Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Vor Biopharma has a beta of 1.73, meaning that its share price is 73% more volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

Vor Biopharma currently has a consensus target price of $43.38, indicating a potential upside of 88.34%. Viking Therapeutics has a consensus target price of $96.63, indicating a potential upside of 191.13%. Given Viking Therapeutics' higher possible upside, analysts clearly believe Viking Therapeutics is more favorable than Vor Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Viking Therapeutics	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A

Summary

Vor Biopharma beats Viking Therapeutics on 7 of the 11 factors compared between the two stocks.

Get Vor Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VOR vs. The Competition

Export

Metric	Vor Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.38B	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	N/A	10.67	269.06	25.28
Price / Sales	N/A	1,294.08	602.43	91.76
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	N/A	16.78	12.91	6.24
Net Income	N/A	-$13.32M	$3.45B	$347.60M
7 Day Performance	-2.70%	1.74%	1.12%	1.07%
1 Month Performance	24.49%	1.60%	1.79%	1.03%
1 Year Performance	-41.84%	56.43%	67.69%	20.77%

Vor Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VOR Vor Biopharma	2.5827 of 5 stars	$23.03 -1.1%	$43.38 +88.3%	-42.4%	$1.38B	N/A	N/A	140	Trending News Earnings Report Analyst Upgrade Analyst Revision
ACAD ACADIA Pharmaceuticals	4.5548 of 5 stars	$29.21 +2.7%	$33.44 +14.5%	+12.8%	$5.03B	$1.07B	13.16	510	Analyst Forecast
DYN Dyne Therapeutics	3.751 of 5 stars	$26.25 +1.4%	$34.42 +31.1%	+112.1%	$4.90B	N/A	N/A	100
CELC Celcuity	3.6751 of 5 stars	$92.79 -0.5%	$155.18 +67.2%	+65.4%	$4.52B	N/A	N/A	40	Trending News Earnings Report Analyst Forecast Gap Down
PBLS Parabilis Medicines	2.0389 of 5 stars	$34.98 -1.7%	$41.67 +19.1%	N/A	$4.13B	N/A	N/A	N/A	News Coverage Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VOR) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vor Biopharma (VOR) Competitors

VOR vs. ACAD, DYN, CELC, PBLS, and VKTX

How does Vor Biopharma compare to ACADIA Pharmaceuticals?

Summary

How does Vor Biopharma compare to Dyne Therapeutics?

Summary

How does Vor Biopharma compare to Celcuity?

Summary

How does Vor Biopharma compare to Parabilis Medicines?

Summary

How does Vor Biopharma compare to Viking Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VOR vs. The Competition

Vor Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vor Biopharma (VOR) Competitors

VOR vs. ACAD, DYN, CELC, PBLS, and VKTX

How does Vor Biopharma compare to ACADIA Pharmaceuticals?

Is ACAD or VOR more profitable?

Which has more risk and volatility, ACAD or VOR?

Does the media refer more to ACAD or VOR?

Which has stronger earnings and valuation, ACAD or VOR?

Do analysts prefer ACAD or VOR?

Do institutionals and insiders have more ownership in ACAD or VOR?

Summary

How does Vor Biopharma compare to Dyne Therapeutics?

Is VOR or DYN more profitable?

Does the media refer more to VOR or DYN?

Do analysts recommend VOR or DYN?

Which has better earnings & valuation, VOR or DYN?

Which has more risk and volatility, VOR or DYN?

Do insiders & institutionals hold more shares of VOR or DYN?

Summary

How does Vor Biopharma compare to Celcuity?

Which has preferable earnings and valuation, VOR or CELC?

Is VOR or CELC more profitable?

Does the media favor VOR or CELC?

Do analysts prefer VOR or CELC?

Do institutionals and insiders hold more shares of VOR or CELC?

Which has more risk and volatility, VOR or CELC?

Summary

How does Vor Biopharma compare to Parabilis Medicines?

Does the media refer more to VOR or PBLS?

Is VOR or PBLS more profitable?

Do institutionals & insiders hold more shares of VOR or PBLS?

Do analysts recommend VOR or PBLS?

Which has preferable earnings & valuation, VOR or PBLS?

Summary

How does Vor Biopharma compare to Viking Therapeutics?

Does the media favor VOR or VKTX?

Is VOR or VKTX more profitable?

Do institutionals & insiders believe in VOR or VKTX?

Which has more risk & volatility, VOR or VKTX?

Do analysts rate VOR or VKTX?

Which has better valuation and earnings, VOR or VKTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VOR vs. The Competition

Vor Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools